Bio Path Financials

Earnings View

Profitability View

Liquidity View

Fundamentals View

Competition View

Bio Path Stock Summary

Bio Path competes with Capricor Therapeutics, NextCure, Pulmatrix, Crinetics Pharmaceuticals, and Aileron Therapeutics. Bio-Path Holdings, Inc. operates as a clinical and preclinical stage oncology focused RNAi nano particle drug development company in the United States. Bio-Path Holdings, Inc. was founded in 2007 and is based in Bellaire, Texas. Bio-Path Holdings operates under Biotechnology classification in the United States and is traded on NASDAQ Exchange. It employs 10 people.

Bio Path Key Financial Ratios

Bio Path Key Balance Sheet Accounts

Bio Path Key Cash Accounts

Bio Financial Ratios Relationships

Comparative valuation techniques use various fundamental indicators to help in determining Bio Path's current stock value. Our valuation model uses many indicators to compare Bio Path value to that of its competitors to determine the firm's financial worth. You can analyze the relationship between different fundamental ratios across Bio Path competition to find correlations between indicators driving Bio Path's intrinsic value. More Info.Bio Path Holdings is rated below average in return on equity category among its peers. It is rated below average in return on asset category among its peers . As of now, Bio Path's Return On Equity is decreasing as compared to previous years. The reason why the comparable model can be used in almost all circumstances is due to the vast number of multiples that can be utilized, such as the price-to-earnings (P/E), price-to-book (P/B), price-to-sales (P/S), price-to-cash flow (P/CF), and many others. The P/E ratio is the most commonly used of these ratios because it focuses on the Bio Path's earnings, one of the primary drivers of an investment's value.

Bio Path Holdings Systematic Risk

Today, most investors in Bio Path Stock are looking for potential investment opportunities by analyzing not only static indicators but also various Bio Path's growth ratios. Consistent increases or decreases in fundamental ratios usually indicate a possible pattern that can be successfully translated into profits. However, when comparing two companies, knowing each company's growth growth rates may not be enough to decide which company is a better investment. That's why investors frequently use static breakdown of Bio Path growth as a starting point in their analysis.

Along with financial statement analysis, the daily predictive indicators of Bio Path help investors to analyze its daily demand and supply, volume, patterns, and price swings to determine the real value of Bio Path Holdings. We use our internally-developed statistical techniques to arrive at the intrinsic value of Bio Path Holdings based on widely used predictive technical indicators. In general, we focus on analyzing Bio Stock price patterns and their correlations with different microeconomic environment and drivers. We also apply predictive analytics to build Bio Path's daily price indicators and compare them against related drivers.

When running Bio Path's price analysis, check to measure Bio Path's market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Bio Path is operating at the current time. Most of Bio Path's value examination focuses on studying past and present price action to predict the probability of Bio Path's future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Bio Path's price. Additionally, you may evaluate how the addition of Bio Path to your portfolios can decrease your overall portfolio volatility.